前列腺癌免疫疗法:是时候超越检查点抑制剂了
Melissa Abel1, Aanika Balaji Warner1, Fatima Karzai1
1Genitourinary Malignancies Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
ImmunoTargets and therapy
|September 19, 2025
概括
前列腺癌已经表现出对免疫检查点抑制剂 (ICI) 的耐药性. 新兴的疗法,如双特异性T细胞参与剂,显示出改变瘤微环境和改善结果的希望.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 前列腺癌研究 研究前列腺癌
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但在前列腺癌中有效性有限.
- 前列腺癌是免疫治疗的早期采用者之一,使用疫苗sipleucel-T.
- 一个普遍的观点表明前列腺癌是抗免疫治疗的.
研究的目的:
- 探索前列腺癌超越ICI的新型免疫治疗策略.
- 调查新疗法改变前列腺癌瘤免疫微环境的潜力.
- 确定有前途的治疗标和方法,以克服前列腺癌中免疫疗法耐药性.
主要方法:
- 对前列腺癌的当前和新兴免疫疗法的审查.
- 对新药临床试验数据的分析.
- 检查针对前列腺癌瘤免疫微环境的策略.
主要成果:
- 尽管sipleucel-T早期取得了成功,但ICI在很大程度上未能改善前列腺癌的结果.
- 包括CAR T细胞,双特异抗体和细胞因子疗法在内的新疗法正在显示出早期的承诺.
- 针对STEAP-1和KLK2等抗原的双特异性T细胞参与剂 (BiTEs) 显示出临床潜力.
结论:
- 前列腺癌对ICI的耐药性需要探索替代免疫治疗方法.
- 新疗法为调节前列腺癌中瘤免疫微环境提供了新的途径.
- 超越ICI可能会显著改善前列腺癌患者的临床结果.
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Vaccines
974
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
974
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


